Form 8-K Mirati Therapeutics, For: Dec 02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Jefferies Reiterates Buy Rating on Mirati Therapeutics (MRTX)
December 6, 2022 8:01 AM ESTJefferies analyst Maury Raycroft reiterated a Buy rating and $149.00 price target on Mirati Therapeutics (NASDAQ: MRTX)
The analyst comments "Abstract data strengthen adagrasib's 1L pembro combo profile, removing worst-case scenarios and showing positive differentiation on safety+efficacy vs AMGN. MRTX said we'll... More
Piper Sandler Reiterates Overweight Rating on Mirati Therapeutics (MRTX)
December 6, 2022 8:00 AM ESTPiper Sandler analyst Swapnil Malekar reiterated an Overweight rating and $110.00 price target on Mirati Therapeutics (NASDAQ: MRTX)
The analyst comments "ESMO-IO abstract revealed that adagrasib+pembro combo in 1L NSCLC patients showed an ORR of 49%, which came in below the Street expectation of ~55%... More
JPMorgan Reiterates Overweight Rating on Mirati Therapeutics (MRTX)
December 6, 2022 8:00 AM ESTJPMorgan analyst Eric Joseph reiterated an Overweight rating and $94.00 price target on Mirati Therapeutics (NASDAQ: MRTX)
The analyst comments "ESMO-IO late-breaking abstracts were published this evening, including an updated look at the phase 2 KRYSTAL-7 trial (adagrasib + pembrolizumab in 1L G12C+ NSCLC). On the whole, we believe the data continue to support the regimens differentiated positioning relative to standard of care and are far more favorable than that of Lumakras + CPI.... More
Morgan Stanley Reiterates Equalweight Rating on Mirati Therapeutics (MRTX)
December 6, 2022 7:59 AM ESTMorgan Stanley analyst Michael Ulz reiterated an Equalweight rating and $100.00 price target on Mirati Therapeutics (NASDAQ: MRTX)
The analyst comments "Data in the abstract from the Ph2 K-7 study (adagrasib + pembro) in 1L NSCLC confirm a tolerable safety profile, as expected. That... More
